ASCO 2014: Combining Advanced Hormone Therapies (Zytiga & Xtandi) Shows Promise for Men with Advanced Prostate Cancer
In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone [...]
ASCO 2014 – ADT May Be Deferred After A Bio-Chemical (PSA only) Relapse in Men with Prostate Cancer
Current practice has been to immediately begin hormone therapy (ADT) as soon as a man has a bio-chemical (PSA only) relapse. A recent presentation at ASCO 2014 has shown that immediate ADT actually offers little [...]
The ASCO 2014 Game Changer – Early Chemotherapy for Some Men Extends Survival
I was asked if there was one item that was a real game changer at the American Society of Clinical Oncologists (ASCO) meeting for men with advanced prostate cancer. The answer is yes, at this [...]
ASCO 2014 – Where the Tumors Are Located Influences Survival
ASCO has become a little more interesting for prostate cancer. Today's item is about a mega-analysis that confirms that the site of metastatic tumors will powerfully predict overall survival (OS) among men with metastatic castration [...]
From ASCO – Early Radiation Might Increase Survival
I have been at American Association of Clinical Oncologists (ASCO) since last Thursday. On the prostate cancer front the most exciting part of the meeting has been our being in Chicago and that the weather [...]
Denosumab is Superior to Zoledronic Acid (ZA) for Pain Interference and Quality of Life
Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will eventually develop debilitating pain that impacts daily functioning and diminishes their quality of life. Based on prior studies, including a phase III trial, the [...]